Stefania Durando
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Cancer Research and Treatments
- Helicobacter pylori-related gastroenterology studies
- Molecular Biology Techniques and Applications
- Genetic factors in colorectal cancer
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Colorectal Cancer Treatments and Studies
- MicroRNA in disease regulation
- Digestive system and related health
- Monoclonal and Polyclonal Antibodies Research
- Cytokine Signaling Pathways and Interactions
- Viral-associated cancers and disorders
- Nanoplatforms for cancer theranostics
- Cancer, Stress, Anesthesia, and Immune Response
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
Candiolo Cancer Institute
2017-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2017-2018
Abstract Gastric cancer is the world's third leading cause of mortality. In spite significant therapeutic improvements, clinical outcome for patients with advanced gastric poor; thus, identification and validation novel targets extremely important from a point view. We generated wide, multilevel platform models, comprising 100 patient-derived xenografts (PDX), primary cell lines, organoids. Samples were classified according to their histology, microsatellite stability, Epstein–Barr virus...
Patient-Derived Xenografts (PDXs), entailing implantation of cancer specimens in immunocompromised mice, are emerging as a valuable translational model that could help validate biologically relevant targets and assist the clinical development novel therapeutic strategies for gastric cancer. More than 30% PDXs generated from carcinoma samples developed human B-cell lymphomas instead These were monoclonal, Epstein Barr Virus (EBV) positive, originated tumorigenic cell cultures displayed...
Gastric and gastroesophageal adenocarcinomas represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, outcome patients with advanced adenocarcinoma is poor. Randomized clinical trials failed to show a survival benefit in molecularly unselected treated anti-EGFR agents.
<p>Organoids contain few or no stroma component and when reinjected in mice originated tumors resembling the corresponding PDXs.</p>
<p>ROC curves of Lee MSI signature predicting genetic status in PDXs and TCGA samples cohorts.</p>
<p>ROC curves of Lee MSI signature predicting genetic status in PDXs and TCGA samples cohorts.</p>
<p>Supplementary Methods</p>
<p>Organoids contain few or no stroma component and when reinjected in mice originated tumors resembling the corresponding PDXs.</p>
<p>Supplementary Methods</p>
<p>Microsatellite instability (MSI) phenotype in primary gastric tumours and their corresponding PDX/ organoid</p>
<div>Abstract<p>Gastric cancer is the world's third leading cause of mortality. In spite significant therapeutic improvements, clinical outcome for patients with advanced gastric poor; thus, identification and validation novel targets extremely important from a point view. We generated wide, multilevel platform models, comprising 100 patient-derived xenografts (PDX), primary cell lines, organoids. Samples were classified according to their histology, microsatellite stability,...
<div>Abstract<p>Gastric cancer is the world's third leading cause of mortality. In spite significant therapeutic improvements, clinical outcome for patients with advanced gastric poor; thus, identification and validation novel targets extremely important from a point view. We generated wide, multilevel platform models, comprising 100 patient-derived xenografts (PDX), primary cell lines, organoids. Samples were classified according to their histology, microsatellite stability,...
<p>Microsatellite instability (MSI) phenotype in primary gastric tumours and their corresponding PDX/ organoid</p>
<p>Supplementary Table 3</p>
<p>Supplementary Figure 4_Revised</p>
<p>Supplementary Figure 1</p>